Receptor, Platelet-Derived Growth Factor beta
"Receptor, Platelet-Derived Growth Factor beta" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A PDGF receptor that binds specifically to the PDGF-B chain. It contains a protein-tyrosine kinase activity that is involved in SIGNAL TRANSDUCTION.
| Descriptor ID |
D020797
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.900.750 D12.776.543.750.630.625.400 D12.776.543.750.750.400.630.400
|
| Concept/Terms |
Receptor, Platelet-Derived Growth Factor beta- Receptor, Platelet-Derived Growth Factor beta
- Receptor, Platelet Derived Growth Factor beta
- Platelet-Derived Growth Factor beta Receptor
- Platelet Derived Growth Factor beta Receptor
- Antigens, CD140b
- PDGFRB
- PDGFR1
- PDGFR beta
- beta, PDGFR
- Receptor, PDGF beta
- CD140b Antigen
- Antigen, CD140b
- PDGF beta Receptor
- CD140b Antigens
|
Below are MeSH descriptors whose meaning is more general than "Receptor, Platelet-Derived Growth Factor beta".
- Chemicals and Drugs [D]
- Enzymes and Coenzymes [D08]
- Enzymes [D08.811]
- Transferases [D08.811.913]
- Phosphotransferases [D08.811.913.696]
- Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
- Protein Kinases [D08.811.913.696.620.682]
- Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]
- Receptor Protein-Tyrosine Kinases [D08.811.913.696.620.682.725.400]
- Receptors, Platelet-Derived Growth Factor [D08.811.913.696.620.682.725.400.900]
- Receptor, Platelet-Derived Growth Factor beta [D08.811.913.696.620.682.725.400.900.750]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptor Protein-Tyrosine Kinases [D12.776.543.750.630]
- Receptors, Platelet-Derived Growth Factor [D12.776.543.750.630.625]
- Receptor, Platelet-Derived Growth Factor beta [D12.776.543.750.630.625.400]
- Receptors, Peptide [D12.776.543.750.750]
- Receptors, Growth Factor [D12.776.543.750.750.400]
- Receptors, Platelet-Derived Growth Factor [D12.776.543.750.750.400.630]
- Receptor, Platelet-Derived Growth Factor beta [D12.776.543.750.750.400.630.400]
Below are MeSH descriptors whose meaning is more specific than "Receptor, Platelet-Derived Growth Factor beta".
This graph shows the total number of publications written about "Receptor, Platelet-Derived Growth Factor beta" by people in this website by year, and whether "Receptor, Platelet-Derived Growth Factor beta" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 1 | 2 |
| 2015 | 1 | 1 | 2 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 0 | 1 |
| 2020 | 2 | 0 | 2 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptor, Platelet-Derived Growth Factor beta" by people in Profiles.
-
Skeletal stem cell fate defects caused by Pdgfrb activating mutation. Development. 2021 12 01; 148(23).
-
Mosaic Mutant Analysis Identifies PDGFRa/PDGFRß as Negative Regulators of Adipogenesis. Cell Stem Cell. 2020 05 07; 26(5):707-721.e5.
-
Dysregulated mesenchymal PDGFR-ß drives kidney fibrosis. EMBO Mol Med. 2020 03 06; 12(3):e11021.
-
Design, synthesis and preclinical evaluation of 5-methyl-N4-aryl-furo[2,3-d]pyrimidines as single agents with combination chemotherapy potential. Bioorg Med Chem Lett. 2018 10 01; 28(18):3085-3093.
-
STAT1 modulates tissue wasting or overgrowth downstream from PDGFRß. Genes Dev. 2017 08 15; 31(16):1666-1678.
-
Synthesis and evaluation of 5-(arylthio)-9H-pyrimido[4,5-b]indole-2,4-diamines as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents. Bioorg Med Chem Lett. 2017 04 01; 27(7):1602-1607.
-
PDGFRß signalling regulates local inflammation and synergizes with hypercholesterolaemia to promote atherosclerosis. Nat Commun. 2015 Jul 17; 6:7770.
-
The design, synthesis and biological evaluation of conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase and microtubule inhibitors as potential antitumor agents. Bioorg Med Chem. 2015 May 15; 23(10):2408-23.
-
Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents. Bioorg Med Chem. 2012 Jul 15; 20(14):4217-25.
-
N4-(3-Bromophenyl)-7-(substituted benzyl) pyrrolo[2,3-d]pyrimidines as potent multiple receptor tyrosine kinase inhibitors: design, synthesis, and in vivo evaluation. Bioorg Med Chem. 2012 Apr 01; 20(7):2444-54.